Late drug-eluting stent thrombosis and erythropoietin: cause and effect?
A case of late thrombosis of a sirolimus-eluting stent, 16 months after implantation, is described. Two weeks prior to presentation with stent thrombosis the patient had a 50% dose increase of longterm erythropoietin. The prothrombotic effect of erythropoietin may have precipitated the thrombotic event.
Gladding
P A
PA
Auckland City Hospital, Greenlane Cardiovascular Service, Park Rd., Grafton, Auckland, New Zealand. patrickg@adhb.govt.nz
Webster
M W
MW
Kay
P
P
D000328:Adult; D015906:Angioplasty, Balloon, Coronary; D002317:Cardiovascular Agents / Q000627:therapeutic use; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use*; D003328:Coronary Thrombosis / Q000209:etiology* / Q000628:therapy; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000009:adverse effects*; D006801:Humans; D008297:Male; D012086:Reoperation; D020123:Sirolimus / Q000627:therapeutic use; D015607:Stents / Q000009:adverse effects*
D002317:Cardiovascular Agents; D020099:Coated Materials, Biocompatible; D004921:Erythropoietin; D020123:Sirolimus